A RANDOMIZED, DOUBLE-BLIND STUDY OF MKC-442 COMBINED WITH VIRACEPT IN PATIENTS WHO ARE EPIVIR + RETROVIR EXPERIENCED AND ARE PROTEASE INHIBITOR- AND NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-NAIVE: